A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.
Corticosteroid Premedication for Infliximab Remains Unnecessarily Common
July 8th 2025Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.
Read More